Hsbc Holdings PLC Makes New Investment in Replimune Group, Inc. (NASDAQ:REPL)

Hsbc Holdings PLC bought a new stake in Replimune Group, Inc. (NASDAQ:REPL) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 14,008 shares of the company’s stock, valued at approximately $175,000.

Other large investors also recently made changes to their positions in the company. Sterling Capital Management LLC grew its position in Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock valued at $26,000 after purchasing an additional 1,655 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Replimune Group by 696.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock valued at $82,000 after buying an additional 5,922 shares during the period. Aster Capital Management DIFC Ltd grew its holdings in shares of Replimune Group by 8,798.9% during the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock valued at $100,000 after acquiring an additional 8,183 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Replimune Group in the fourth quarter worth $137,000. Finally, Sei Investments Co. purchased a new stake in shares of Replimune Group during the fourth quarter worth $148,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Price Performance

NASDAQ REPL opened at $7.71 on Monday. Replimune Group, Inc. has a fifty-two week low of $4.92 and a fifty-two week high of $17.00. The stock’s 50-day moving average is $9.36 and its two-hundred day moving average is $11.48. The firm has a market cap of $593.79 million, a P/E ratio of -2.51 and a beta of 0.68. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). On average, analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on REPL. HC Wainwright boosted their target price on Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. BMO Capital Markets lifted their price target on Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. increased their price objective on Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Replimune Group presently has an average rating of “Buy” and an average price target of $19.43.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.